Statistical models for predicting response to interferon-α and spontaneous seroconversion in children with chronic hepatitis B

Journal of Viral Hepatitis

Volumn 7, Issue 2, 2000, Pages 144-152

  Comanor, L ^a   Minor, J ^a   Conjeevaram, H S ^b   Roberts, E A ^c   Alvarez, F ^d   Bern, E M ^e   Goyens, P ^f   Rosenthal, P ^g   Lachaux, A ^h   Shelton, M ⁱ   Sarles, J ^j   Sokal, E M ^k  

^a BAYER CORPORATION   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d UNIVERSITY OF MONTREAL   (Canada)

^e UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^f HOP UNIV DES ENFANTS REINE FABIOLA   (Belgium)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h EDOUARD HERRIOT HOSPITAL   (France)

ⁱ Cook Children's Medical Center ^*  (United States)

^j TIMONE HOSPITAL   (France)

^k CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

more..

Author keywords

HBV DNA; IFN therapy; Paediatrics; SMILES prognostic models

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; ASPARTATE AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN; RECOMBINANT ALPHA2B INTERFERON; VIRUS DNA;

ADOLESCENT; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HEPATITIS B; HUMAN; LIVER BIOPSY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; STATISTICAL MODEL; TREATMENT OUTCOME;

ADOLESCENT; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; DISEASE SUSCEPTIBILITY; FEMALE; HEPATITIS B, CHRONIC; HUMANS; INFANT; INTERFERON-ALPHA; MALE; MODELS, STATISTICAL; SOFTWARE;

EID: 0034026191     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.2000.00205.x     Document Type: Article

References (31)

1. 1 Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997; 336: 347-356.
2. 2 Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. Ann Intern Med 1993; 119: 312-323.
3. 3 Sokal EM, Conjeevaram HS, Roberts EA et al. Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial. Gastroenterology 1998; 114: 988-995.
4. 4 Gottrand F, Michaud L, Guimber D et al. Influence of recombinant Interferon alpha on nutritional status and growth pattern in children with chronic viral hepatitis. Eur J Pediatr 1996; 155: 1031-1034.
5. 5 Giacchino R, Timitilli A, Cristina E et al. Repeated course of Interferon treatment in chronic hepatitis B in childhood. Arch Virol (Suppl) 1992; 4: 273-276.
6. 6 Torre D. Tambini R. Interferon-α therapy for chronic hepatitis B in children: a meta-analysis. Clin Infect Dis 1996; 23: 131-137.
7. 7 Vajro P, Migliaro F, Fontanella A, Orso G. Interferon: a meta-analysis of published studies in pediatric chronic hepatitis B. Acta Gastroenterol Belg 1998; 61: 219-223.
8. 8 Ruiz-Moreno M, Rua MJ, Molina J et al. Prospective, randomized controlled trial of interferon-alpha in children with chronic hepatitis B. Hepatology 1991; 13: 1035-1039.
9. 9 Lau DT-Y, Comanor L, Minor JM, Everhart JE, Wuestehube LJ, Hoofnagle JH. Statistical models for predicting a beneficial response to interfcron-α in patients with chronic hepatitis B. J Viral Hepat 1998; 5: 105-114.
10. 10 Habersetzer F, Trépo C, Minor J, Comanor L. Predictions of liver histology from laboratory tests and demographic information. Lancet 1998; 352: 907-908.
11. 11 Desmet VJ, Gerber M, Hoofnagle JH. Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 1513-1520.
12. 12 Sheth SG, Flamm SL, Gordon FD, Chopra S. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1998; 93: 44-48.
13. 13 Williams ALB, Hoofnagle JH. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. Gastroenterology 1988; 95: 734-739.
14. 14 ter Borg F, ten Kate FJ. Cuypers HT et al. Relation between laboratory test results and histological activity in individuals positive for hepatitis B surface antigen and antibodies to hepatitis B e antigen. Lancet 1998; 351: 1914-18.
15. 15 Krajden M, Minor J, Cork L, Comanor L. Multi-measurement method comparison of three commercial hepatitis B virus DNA quantification assays. J Viral Hepat 1998; 5: 415-422.
16. 16 Digene product insert. A Signal Amplified Solution Hybridization Antibody Capture Assay for the Chemiluminescent Detection and Quantification of Hepatitis B Virus (HBV) DNA in Serum. Beltsville, MD: Digene Diagnostics, Inc., 1996.
17. 17 Kuhns M, McNamara AL, Cabal CM et al. A new assay for the quantitative detection of hepatitis B viral DNA in human serum. In: Zuckerman AJ, ed. Viral Hepatitis and Liver Disease. New York: Alan R. Liss, Inc., 1988: 258-262.
18. 18 Hendricks DA, Stowe BS, Hoo BS et al. Quantitation of HBV DNA in human serum using a branched DNA (bDNA) signal amplification assay. Am J Clin Pathol 1995; 104: 537-546.
19. 19 Goubau P, Sokal E, Croonen L. Quantitation of hepatitis B virus DNA by Abbott's liquid hybridization and by Chiron's branched DNA in Interferon treated children. Hepatol Res 1999; 14: 171-175.
20. 20 Kapke GF, Watson G, Sheffler S, Hunt D, Frederick C. Comparison of the Chiron Quantiplex branched DNA (bDNA) assay and the Abbott Genostics solution hybridization assay for quantification of hepatitis B viral DNA. J Viral Hepat 1997; 4: 67-75.
21. 21 Minor JM, Namini H. Analysis of clinical data using neural nets. J Biopharm Statist 1996; 6: 83-104.
22. 22 Comanor L, Minor J. Inventors; Chiron Corporation, assignee. Methods and Apparatus for Predicting Therapeutic Outcomes. US Patent 5 860 917. January 19, 1999.
23. 23 Kshirsager AM. Multivariate Analysis. New York: Marcel Dekker, 1972.
24. 24 Lau DT, Everhart J, Kleiner DE et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 1997; 113: 1660-1667.
25. 25 Gregorio GV, Jara P, Hierro L et al. Lymphoblastoid interferon alfa with or without steroid pretreatment in children with chronic hepatitis B: a multicenter controlled trial. Hepatology 1996; 23: 700-707.
26. 26 Bruguera M, Amat L, Garcia O et al. Treatment of chronic hepatitis B in children with recombinant alfa interferon. Different response according to age at infection. J Clin Gastroenterol 1993; 17: 296-299.
27. 27 Barbera C, Bortolotti F, Crivellaro C et al. Recombinant interferon-alpha 2a hastens the rate of HBeAg clearance in children with chronic hepatitis B. Hepatology 1994; 20: 287-290.
28. 28 Ruiz-Moreno M, Camps T, Jimenez J et al. Factors predictive of response to interferon therapy in children with chronic hepatitis B. J Hepatol 1995; 22: 540-544.
29. 29 Evans AA, Fine M, London WT. Spontaneous seroconversion in hepatitis B antigen-positive chronic hepatitis B. implications for interferon therapy. J Infect Dis 1997; 176: 845-850.
30. 30 Carithers RLJ. Effect of interferon on hepatitis B. Lancet 1998; 351: 157.
31. 31 Glaxo Wellcome I. FDA Approves Epivir(R)-HBV™ (lamivudine), the First Oral Treatment for Chronic Hepatitis B. Company Press Release December 9, 1998.